- Home
- LIEN vs RCEL Comparison
LIEN vs RCEL Comparison
Compare LIEN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- RCEL
- Stock Information
- Founded
- LIEN 2021
- RCEL N/A
- Country
- LIEN United States
- RCEL United States
- Employees
- LIEN N/A
- RCEL N/A
- Industry
- LIEN
- RCEL Medical/Dental Instruments
- Sector
- LIEN
- RCEL Health Care
- Exchange
- LIEN NYSE
- RCEL Nasdaq
- Market Cap
- LIEN 234.6M
- RCEL 161.5M
- IPO Year
- LIEN 2022
- RCEL N/A
- Fundamental
- Price
- LIEN $10.75
- RCEL $5.71
- Analyst Decision
- LIEN Buy
- RCEL Strong Buy
- Analyst Count
- LIEN 2
- RCEL 4
- Target Price
- LIEN N/A
- RCEL $16.50
- AVG Volume (30 Days)
- LIEN 61.1K
- RCEL 308.7K
- Earning Date
- LIEN 08-07-2025
- RCEL 08-07-2025
- Dividend Yield
- LIEN 12.66%
- RCEL N/A
- EPS Growth
- LIEN 30.25
- RCEL N/A
- EPS
- LIEN 1.15
- RCEL N/A
- Revenue
- LIEN $30,828,508.00
- RCEL $71,661,000.00
- Revenue This Year
- LIEN $154.46
- RCEL $57.16
- Revenue Next Year
- LIEN $10.64
- RCEL $36.69
- P/E Ratio
- LIEN $9.31
- RCEL N/A
- Revenue Growth
- LIEN 151.96
- RCEL 41.35
- 52 Week Low
- LIEN $9.70
- RCEL $4.71
- 52 Week High
- LIEN $13.38
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- RCEL 49.89
- Support Level
- LIEN N/A
- RCEL $5.13
- Resistance Level
- LIEN N/A
- RCEL $5.87
- Average True Range (ATR)
- LIEN 0.00
- RCEL 0.31
- MACD
- LIEN 0.00
- RCEL 0.14
- Stochastic Oscillator
- LIEN 0.00
- RCEL 83.19
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.